DaVita Inc. DVA has been gaining from its DaVita Kidney Care. The optimism led by a solid second-quarter 2023 performance and the acquisition of dialysis centers are expected to contribute further.
DaVita is set to announce its fourth-quarter results soon, with analysts forecasting a double-digit increase in the company’s bottom-line figure.
DaVita Inc. DVA is well-poised for growth in the coming quarters, courtesy of strength in its DaVita Kidney Care. The optimism led by a solid second-quarter 2023 performance and the acquisition of ...
DaVita Inc. DVA has been gaining from its business model. The optimism, led by a decent third-quarter 2025 performance and ...
Health care conversations have outgrown the concept of transformation; what we need now is a revolution, driven by the capabilities of cutting-edge technology. As DaVita continues to invest in new ...
Concern over weight loss drug Semaglutide has caused an unjustified sell-off in DaVita shares. Dialysis is essential to life for people with late-stage chronic kidney disease, making DaVita ...
DaVita HealthCare Partners is reporting earnings from the last quarter on August 3. Analysts expect DaVita HealthCare Partners will report earnings per share of $1.71. Go here to follow DaVita ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results